-

HighTide Therapeutics to Present at HC Wainwright’s 4th Annual NASH Investor Conference

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patients with non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that Liping Liu, Founder and Chief Executive Officer, and Adrian M. Di Bisceglie, Chief Medical Officer, will present virtually at the HC Wainwright 4th Annual NASH Conference on Monday, October 5, 2020 at 9:30am EDT.

About HighTide Therapeutics

HighTide Therapeutics Inc. is dedicated to the development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unmet medical needs. HTD1801 is a new molecular entity being developed for the treatment of NASH and PSC. HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. For additional information, please visit https://hightidetx.com/.

Contacts

Jeffrey Dao
ir@hightidetx.com

Industry:

HighTide Therapeutics Inc.

Release Versions
English

Contacts

Jeffrey Dao
ir@hightidetx.com

More News From HighTide Therapeutics Inc.

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 – 8, 2022). A poster presentation titled “Effects of HTD1801 on t...

HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development

ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development. Mr. Ripley has 25 years of experience in pharmaceutical business development. Most recently he served as Head of Global Business Development for Alpha Biopharma. Mr. Ripley will report to D...

HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China. Led by Professor Linong Ji, Director of the D...
Back to Newsroom